New drug aims to reduce kidney damage in chronic disease

NCT ID NCT07716618

Ongoing Disease control Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This clinical trial tests an experimental drug called SAL0120 in people with chronic kidney disease (CKD). The study aims to see if different doses of SAL0120 can reduce protein in the urine, a key marker of kidney damage. Participants are randomly assigned to receive either SAL0120 or a placebo for 12 weeks. The trial includes adults aged 18 to 75 with moderate to severe CKD.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called SAL0120
What this could lead to: If successful, this could point toward a new treatment option to slow kidney damage in chronic kidney disease.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not confirm effectiveness or safety for wider use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE

Contacts and locations

Show contact details

Locations

West China Hospital of Sichuan University

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.